Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $298.09

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given an average recommendation of “Moderate Buy” by the twenty-four brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and eighteen have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $298.09.

Several analysts recently commented on ALNY shares. JPMorgan Chase & Co. raised their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. TD Cowen lifted their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Needham & Company LLC reissued a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, Raymond James boosted their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the sale, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock worth $2,540,455 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ALNY. Huntington National Bank grew its stake in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the period. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Ashton Thomas Private Wealth LLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth about $26,000. Washington Trust Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $42,000. Finally, True Wealth Design LLC raised its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 0.1 %

NASDAQ ALNY opened at $245.44 on Wednesday. The stock has a market capitalization of $31.66 billion, a P/E ratio of -93.68 and a beta of 0.32. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The stock has a fifty day moving average of $267.01 and a 200-day moving average of $248.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period last year, the firm earned $1.15 EPS. The business’s revenue was down 33.3% on a year-over-year basis. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post -2.21 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.